FDA To Respond To IoM’s Rx Safety Recommendations
This article was originally published in The Pink Sheet Daily
Executive Summary
Commissioner von Eschenbach will detail how FDA plans to improve its oversight of drug risk issues.
You may also be interested in...
FDA Reform Bill Would Give Commissioner Fixed Term, Add Review Board
The Transforming the Regulatory Environment to Accelerate Access to Treatments Act would mandate a fixed six-year term for the FDA commissioner and the agency’s centers would receive a chief medical policy officer, according to a draft of the bill.
FDA Reform Bill Would Give Commissioner Fixed Term, Add Review Board
The Transforming the Regulatory Environment to Accelerate Access to Treatments Act would mandate a fixed six-year term for the FDA commissioner and the agency’s centers would receive a chief medical policy officer, according to a draft of the bill.
FDA Reform Bill Gives Commissioner Fixed Term, Adds Review Board
The Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act would mandate a fixed six-year term for the FDA commissioner, according to a draft of the bill obtained by “The Pink Sheet.” FDA’s centers would receive a chief medical policy officer.